An Open-Label, Multicenter, Phase I Study Evaluating the Safety, Pharmacokinetics, and Efficacy of BA3182, A Bispecific Epithelial Cell Adhesion Molecule (EPCAM)/CD3 Antibody, in Patients with Advanced Adenocarcinoma
Details
The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma
Eligibility
You can join if...
Inclusion Criteria
age 18 or older
Histologically or cytologically confirmed locally advanced unresectable or metastatic
adenocarcinoma and for whom available standard of care (SoC) therapy has failed or no
curative therapy is available or are not eligible, intolerant to, standard therapy.
Provide written informed consent (patient or legally acceptable representative)
Exclusion Criteria
-Incomplete recovery from the effects of major surgery or significant traumatic injury
before the first dose of study treatment.
Women who are pregnant or breastfeeding
Administered a live vaccine ≤ 4 weeks before enrollment.